K222087 is an FDA 510(k) clearance for the SCIg60 Infusion System. This device is classified as a Immunoglobulin G (igg) Infusion System (Class II - Special Controls, product code PKP).
Submitted by Emed Technologies Corporation (El Dorado Hills, US). The FDA issued a Cleared decision on October 13, 2022, 90 days after receiving the submission on July 15, 2022.
This device falls under the General Hospital FDA review panel. Regulated under 21 CFR 880.5725. An Immunoglobulin G (igg) Infusion System Is A Prescription Device Intended For Subcutaneous Delivery Of Immunoglobulin G (igg) In Accordance With The Fda Approved Labeling..
| 510(k) Number | K222087 FDA.gov |
| FDA Decision | Cleared Substantially Equivalent - Traditional 510(k) (SESE) |
| Date Received | July 15, 2022 |
| Decision Date | October 13, 2022 |
| Days to Decision | 90 days |
| Submission Type | Traditional |
| Review Panel | General Hospital (HO) |
| Summary | Summary PDF |
| Product Code | PKP — Immunoglobulin G (igg) Infusion System |
| Device Class | Class II - Special Controls |
| CFR Regulation | 21 CFR 880.5725 |
| Definition | An Immunoglobulin G (igg) Infusion System Is A Prescription Device Intended For Subcutaneous Delivery Of Immunoglobulin G (igg) In Accordance With The Fda Approved Labeling. |